Published in Pharma Law Weekly, June 1st, 2004
The study included 54 healthy volunteers and was intended to assess safety, tolerability, and pharmacokinetics following a single oral administration. Results from the study suggest AVP 13358 was well tolerated at all doses. The study also demonstrated AVP 13358 was detectable in the bloodstream at all doses administered and remains in circulation long enough to allow once or twice daily dosing.
"We are very pleased to see the level of exposure, tolerability and the promising pharmacokinetic profile that our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly